Amendments to the Claims:

Please amend claims 56 and 82 as follows.

Please cancel claims 74 to 78 without prejudice or disclaimer.

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims:

1 to 55 (cancelled).

- 56. (currently amended) An isolated nucleic acid molecule selected from the group consisting of:
- (a) an isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or the complete complement thereof;
- (b) an isolated nucleic acid molecule having at least 95% nucleotide sequence identity with the entire contiguous open reading frame of SEQ ID NO: 1 and encoding a protein capable of phosphorylating ribosomal S6 protein;
- (c) an isolated nucleic acid molecule which hybridizes to the nucleotide sequence of SEQ ID NO: 1 or the <u>complete</u> complement thereof under conditions which employ 0.1x SSC at 68°C and which encodes a protein capable of phosphorylating ribosomal S6 protein; and
- (d) an isolated nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO: 2.
 - 57. (cancelled)
- 58. (previously presented) An isolated nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO: 2 wherein the fragment is capable of phosphorylating ribosomal S6 protein.
- 59. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule comprises nucleotides 77-1561 of SEQ ID NO: 1.
- 60. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule consists of nucleotides 77-1561 of SEQ ID NO: 1.

- 61. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule consists of nucleotides 77-1564 of SEQ ID NO: 1.
- 62. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule comprises nucleotides 116-1561 of SEQ ID NO: 1.
- 63. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule consists of nucleotides 116-1561 of SEQ ID NO: 1.
- 64. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule consists of nucleotides 116-1564 of SEQ ID NO: 1.
- 65. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule contains a nucleotide substitution at a position corresponding to nucleotides 1277, 1278 or 1279 of SEQ ID NO: 1.
- 66. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule encodes a protein comprising an aspartic acid substitution for threonine at amino acid 401 of SEQ ID NO: 2.
 - 67. (cancelled)
- 68. (previously presented) The isolated nucleic acid molecule of any one of claims 56 and 58-66, wherein the nucleic acid molecule is operably linked to one or more expression control elements.
- 69. (previously presented) A vector comprising the isolated nucleic acid molecule of any one of claims 56 and 58-66.
- 70. (previously presented) A host cell transformed to contain the nucleic acid molecule of any one of claims 56 and 58-66.

- 71. (previously presented) A host cell comprising the vector of claim 69.
- 72. (previously presented) The host cell of claim 70, wherein said host cell is selected from the group consisting of prokaryotic hosts and eukaryotic hosts.
- 73. (previously presented) A method for producing a protein comprising the step of culturing a host cell of claim 70 under conditions in which the protein encoded by the nucleic acid molecule is expressed.

74 to 78 (cancelled)

- 79. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule in (b) has at least 97% nucleotide sequence identity with the entire contiguous open reading frame of SEQ ID NO: 1.
- 80. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule in (b) has at least 98% nucleotide sequence identity with the entire contiguous open reading frame of SEQ ID NO: 1.
- 81. (previously presented) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule in (b) has at least 99% nucleotide sequence identity with the entire contiguous open reading frame of SEQ ID NO: 1.
- 82. (currently amended) The isolated nucleic acid molecule of claim 56, wherein the nucleic acid molecule hybridizes to the nucleotide sequence of SEQ ID NO: 1 or the <u>complete</u> complement thereof under conditions which employ 0.1x SSC at 68°C.

Attorney Docket **040750-5002**U.S. Application **09/762,258**Page **6**

Supplemental Response to the Office Action

The specification has been amended on page 14 to include text incorporated by reference on page 16, line 27 and page 47, lines 2 to 3. Copies of the pages from the incorporated reference are attached with the relevant text highlighted. In addition, claims 56 and 82 have been amended to include the "complete" complement of SEQ ID NO: 1 and withdrawn claims 74 to 78 have been cancelled without prejudice or disclaimer.

Conclusion

Applicants respectfully request reconsideration of the subject application in view of the amended claims and the above remarks. It is respectfully submitted that this application is now in condition for allowance. Should the Examiner believe it to be useful, another interview with the Examiner is respectfully requested in order to discuss the foregoing claims.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application, including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a constructive petition for extension of time in accordance with 37 C.F.R. 1.136(a)(3).

Dated: July 19, 2004 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 202-739-3000 Respectfully submitted

Morgan, Lewis & Bockius LLP

West & myth

Robert Smyth
Registration No. 50,801